-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastric palsy is a serious chronic disease characterized by delayed gastric drain and recurrent symptoms of the upper digestive tract.
and gastric palsy are often associated with serious damage to social function and ability to work.
of mild paralysis include nausea, vomiting, bloating, fullness after meals, abdominal discomfort and pain.
is the most common symptom of gastric palsy, with more than 90 per cent of people with palsy reported to have symptoms of nausea.
The incidence of gastric palsy is 6.3 to 17.2 per 100,000 people per year, but the actual prevalence rate is estimated at 50.5 per 100,000 people, so more than 5 million people in the United States may be affected by gastric palsy.
pathophysiological mechanisms for gastrointestinal palsy are complex and may involve neuromuscular dysfunction and sensory neuropathy, leading to delays in gastric emptying, nausea and pain.
people realize that because the relationship between upper digestive tract symptoms and gastric emptying rate is weak, treatment should be directed not only to the symptoms of mild gastric palsy, but also to gastrointestinal motivation.
fda-approved drug for gastric palsy is methicilopamine, but its use should not be limited to three months due to adverse neurological reactions to delayed movement disorders.
inhibitors of
-speed peptides1 (TACR1), also known as neurostid-1s (NK1R), have been approved for the treatment of nausea and vomiting, showing good inhibitory effects on nausea.
NK1R antagonists may affect stomach peristalsis through local action and directly affect nerve transmission in the brain region responsible for nausea and vomiting, thus having a dual and potential therapeutic effect in gastric palsy.
Tradipitant is an effective NK1R selective inhibitor that can be used to treat gastric palsy by inhibiting the brain's nausea and vomiting center and stimulating smooth muscle peristaltic movements in the intestines.
, this study aims to explore the safety and effectiveness of NK1R antagonist tradipitant in patients with iddly ill or diabetic gastric palsy.
conducted a double-blind trial of 152 adults with gastric palsy at 47 U.S. medical centers between November 2016 and December 2018.
participants were randomly divided into two groups, taking 85 mg Tradipitant (n s 77) or a placebo (n s 75) for 4 weeks.
patients' clinical symptoms were assessed using a gastric palsy major symptom index score and questionnaires reported by other patients.
the researchers also recorded changes in average nausea levels from baseline to week 4.
compared to placebo, patients treated with tradeitant had a significantly lower nausea score in week 4 (P s.0099) and a significant increase in nausea-free days in week 4 (up 28.8 percent month-on-month ;P s.0160).
Compared to the placebo group, patients with nausea and vomiting at baseline (n s 101) had a greater reduction in odor and vomiting (1.4) (P <.0001.0003>
。